Oncotarget

Research Papers:

Percutaneous laser ablation: a new contribution to unresectable high-risk metastatic retroperitoneal lesions?

Tian’an Jiang, Zhuang Deng, Guo Tian, Fen Chen, Haiwei Bao, Ju Li and Weilin Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:2413-2422. https://doi.org/10.18632/oncotarget.13897

Metrics: PDF 1734 views  |   HTML 2067 views  |   ?  


Abstract

Tian’an Jiang1, Zhuang Deng2, Guo Tian3,4, Fen Chen2, Haiwei Bao2, Ju Li2 and Weilin Wang2,4

1 Department of Ultrasound Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

2 Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

3 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

4 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Correspondence to:

Weilin Wang, email:

Keywords: laser ablation, ablation, retroperitoneal tumor, lymph nodes, oncology

Received: July 25, 2016 Accepted: November 22, 2016 Published: December 10, 2016

Abstract

BACKGROUND & AIMS: Metastasis in retroperitoneal lymph nodes is one of the signs of advanced stage or terminal stage of malignancy. We performed a trial to assess the safety and efficacy of ultrasonography (US)-guided local neodymium-doped yttrium aluminum garnet (Nd:YAG) laser ablation for metastatic lymph nodes in the retroperitoneal region.

METHODS: We evaluated 4 cases of retroperitoneal metastatic lymph nodes treated using US-guided Nd:YAG laser ablation. Additionally, we reviewed the PubMed database for articles on thermal ablation of retroperitoneal lesions until March 2016, without language limitations.

RESULTS: In our study, all lesions were nearly completely ablated with mild discomfort, including pain and fever at the 3-month follow-up. In the literature review, a total of 398 patients with 491 retroperitoneal tumors were identified, and complications after the procedure included enterovesical fistula, fecal incontinence, and hematoma.

CONCLUSIONS: Percutaneous laser ablation could be a theoretically promising approach for retroperitoneal metastatic lesions. ClinicalTrials.gov number: NCT02822053.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13897